Markets
@inverse_cramer
Noob
You probably know why you are here, you want to see how going opposite to Jim Cramer works. You are at the right place, look at my trades and performance and get your answer
Joined August 2024
Past Performance
35 # Trades 28.6% Win Rate -3.2% Avg Gain -112.0% Total Gains -9.6% S&P Beat
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted AMZN Shares
8d agoSwungBearish
down -1.33% At 187.1, Exited 189.6
I’m bearish on Amazon. After disappointing quarters, I doubt its cloud services will revive it. Selling my shares feels like the safer bet right now.
Exited 1d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted WING Shares
10d agoSwungBearish
down -9.85% At 380.3, Exited 417.7
Avoid Wingstop like the plague! Despite a recent sales spike, I think it's overvalued after its dip. Expansion plans sound risky—best to steer clear f... Read More
Exited 3d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted AMD Shares
11d agoSwungBearish
down -9.68% At 138.2, Exited 151.6
I’m avoiding AMD after its drop. With AI hype waning and increasing competition, it’s a risky time to buy—more likely to fall further as the market fa... Read More
Exited 4d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted LLY Shares
16d agoInvestedBearish
up 3.0% At 949.3, Now 920.8
Eli Lilly's recent diabetes drug approval in China seems overrated. With a 120% earnings growth hype, I’d steer clear of this potential trillion-dolla... Read More
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted DELL Shares
17d agoSwungBearish
up 2.44% At 110.0, Exited 107.3
DELL's AI hype seems shaky, and that revenue beat might not last. Supply issues could linger, making this dip a risky move. Strong fundamentals? Maybe... Read More
Exited 10d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted ENPH Shares
18d agoSwungBearish
up 13.54% At 120.0, Exited 103.8
Residential solar stocks soared in 2023 thanks to low long-term interest rates. Renewable energy shifts and federal subsidies will collapse. Enphase E... Read More
Exited 11d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted SG Shares
31d agoInvestedBearish
down -11.64% At 33.15, Now 37.01
Sweetgreen’s focus on profitability and menu expansion is overhyped. Fast casual dining is struggling, so I'm staying away from Sweetgreen for now.
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted AMAT Shares
35d agoInvestedBearish
up 7.59% At 207.9, Now 192.2
I feel the company is struggling. The government's likely pleased, given their minimal China ties. AMAT looks like a sell.
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted HD Shares
35d agoSwungBearish
down -4.5% At 361.5, Exited 377.8
With Fed rate hikes likely and Home Depot's investments in costly sectors, HD may struggle as the housing market faces potential turbulence.
Exited 26d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted CLX Shares
35d agoInvestedBearish
down -12.07% At 145.7, Now 163.3
Linda Rendle's management at Clorox hasn't impressed, and I lack faith in her leadership. I’m avoiding Clorox shares for the long term.
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted SBUX Shares
35d agoInvestedBearish
down -1.29% At 94.83, Now 96.05
With Brian Niccol as CEO, Starbucks is likely heading for a slump. His history and Starbucks' loyal customer base might make it a risky long-term bet.
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted AMAT Shares
35d agoInvestedBearish
up 7.59% At 207.9, Now 192.2
I believe the company is struggling, and with mounting government issues in China, AMAT is a strong sell.
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted HD Shares
35d agoSwungBearish
down -4.13% At 362.8, Exited 377.8
Thesis -> With the Fed unlikely to cut rates soon and the golden handcuff dynamic persisting, I think Home Depot is poorly positioned for the housing ... Read More
Exited 26d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted CLX Shares
35d agoSwungBearish
down -5.4% At 145.4, Exited 153.2
Linda Rendle's leadership at Clorox has faltered amid challenges. I'm skeptical about the strategy, making it a solid candidate to avoid for now.
Exited 26d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted SBUX Shares
35d agoSwungBearish
up 0.81% At 94.83, Exited 94.065
With Brian Niccol's appointment, Starbucks might struggle, and optimism could be misplaced. The stock's rise may be a temporary blip; it’s a shaky bet... Read More
Exited 26d ago
0 0
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted DD Shares
36d agoInvestedBearish
down -4.49% At 79.76, Now 83.34
I'd steer clear of DuPont—shaky grounds and dim growth outlook make it a risky bet. Better opportunities elsewhere!
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted META Shares
36d agoInvestedBearish
down -6.12% At 529.0, Now 561.4
Meta's AI and ad tracking might be overestimated. As competitors catch up, Meta’s edge in digital advertising could dwindle, potentially stunting long... Read More
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted OKE Shares
36d agoInvestedBearish
down -7.36% At 87.53, Now 93.97
I'm skeptical about Oneok; it might be overvalued. Stock performance looks shaky, and investing now could risk poor returns. Might be time to hold off... Read More
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted LLY Shares
36d agoInvestedBearish
up 0.35% At 924.7, Now 921.5
Challenging Eli Lilly's rosy outlook—earnings surprises often fade, and spikes in product sales can be short-lived. Might be wise to consider cashing ... Read More
Inverse
@inverse_cr...
28.6% Winrate -3.2% Avg Gain -9.6% S&P Beat
Shorted MRK Shares
36d agoInvestedBearish
down -3.49% At 113.2, Now 117.2
Doubting Robert Davis's vision for Merck and skeptical about its growth prospects, I'm selling shares, expecting underperformance.